Clinical Trial Update: Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating effects on lipoprotein metabolism from PCSK9 inhibition using a monoclonal antibody in primary hyperlipidemia and mixed dyslipidemia; c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia
• Mixed Dyslipidemia

Drugs mentioned

• PCSK9 monoclonal antibody (PCSK9 inhibitor (monoclonal antibody))

Snippet

Sponsor: Amgen | Conditions: Primary Hyperlipidemia and Mixed Dyslipidemia | Phase 3 | Status: COMPLETED | Results posted: 2016-08-31